Internal Medicine, Hematology & Oncology · Dearborn, MI
NPI
1811138787
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
13530 Michigan Ave Ste 280
Dearborn, MI, 48126
Phone (313) 476-3940
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.4M
351,759 services
Medicare patients, 2024
830
Average age 72
Drug cost, 2024
$14.8M
6,166 prescriptions
Company payments, 2025
$86K
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Faisal Musa was code J1439 (injection, ferric carboxymaltose, 1 mg), 138,000 times for 94 patients. In total Faisal Musa billed 351,759 services in 111 codes, and Medicare paid $5.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 138,000 | 94 | $0.87 | $120K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 24,400 | 17 | $44.57 | $1.1M |
| J0897 Injection, denosumab, 1 mg | Office | 23,400 | 46 | $20.57 | $481K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 10,500 | 19 | $0.11 | $1,114 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 8,052 | 21 | $21.05 | $169K |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 6,750 | 15 | $50.86 | $343K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,202 | 43 | $0.09 | $285 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,890 | 38 | $0.72 | $1,357 |
| 85025 Blood Count | Office | 1,709 | 523 | $7.59 | $13K |
| 99214 Office E&M - Established | Office | 1,287 | 504 | $96.85 | $125K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 800 | 18 | $0.07 | $58.98 |
| 96375 Injection Administration | Office | 720 | 60 | $11.87 | $8,544 |
| 96413 Chemotherapy Administration | Office | 658 | 80 | $98.93 | $65K |
| 96372 Injection Administration | Office | 645 | 162 | $10.58 | $6,823 |
| J9045 Injection, carboplatin, 50 mg | Office | 411 | 15 | $2.65 | $1,088 |
By year: 2022 $3.9M for 173,942 services; 2023 $5.1M for 247,241 services; 2024 $5.4M for 351,759 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,709 | 523 | $7.59 | $13K |
| 36415 Venipuncture Blood Collection | 144 | 121 | $8.65 | $1,246 |
Medicare prescription drug claims, 2024
In 2024, the drug Faisal Musa prescribed most often to Medicare patients was Eliquis (Apixaban), with 442 prescriptions and refills. In total Faisal Musa wrote 6,166 Medicare prescriptions that cost $14.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 442 | 788 | 132 | $438K |
| Letrozole Generic | 380 | 895 | 104 | $15K |
| Prochlorperazine Maleate Generic | 344 | 348 | 186 | $4,524 |
| Prednisone Generic | 310 | 415 | 116 | $1,616 |
| Acyclovir Generic | 294 | 497 | 74 | $4,869 |
| Dexamethasone Generic | 234 | 274 | 97 | $4,396 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 209 | 290 | 52 | $829 |
| Xarelto Rivaroxaban | 202 | 371 | 51 | $203K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 151 | 151 | 53 | $2,009 |
| Duloxetine Hcl Generic | 148 | 245 | 37 | $2,192 |
| Abiraterone Acetate Generic | 144 | 152 | 26 | $220K |
| Xtandi Enzalutamide | 123 | 123 | 14 | $1.6M |
| Hydrocortisone Generic | 98 | 114 | 40 | $3,113 |
| Hydroxyurea Generic | 96 | 212 | 26 | $2,547 |
| Potassium Chloride Generic | 94 | 102 | 47 | $826 |
Brand drugs: 1,636 claims; generic drugs: 4,530 claims; opioid claims: 259.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Faisal Musa $86K ($86K in general payments such as food, travel and fees) from 27 companies. The largest payer was Regeneron Healthcare Solutions, Inc. with $48K.
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. REGN | 59 | $48K |
| AstraZeneca Pharmaceuticals LP AZN | 21 | $20K |
| Daiichi Sankyo Inc. 4568.T | 15 | $11K |
| Geron Corporation GERN | 7 | $2,841 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $1,899 |
| Janssen Biotech, Inc. JNJ | 8 | $1,467 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $138 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 1 | $127 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 1 | $126 |
| Axsome Therapeutics, Inc. AXSM | 1 | $111 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.